Alto Neuroscience Announces Positive Phase 1 Results for ALTO-101, a Novel PDE4 Inhibitor in Development for Schizophrenia
Alto Neuroscience, Inc. (ANRO)
Company Research
Source: Business Wire
– ALTO-101 demonstrated a favorable pharmacokinetic and tolerability profile; novel transdermal formulation delivered significantly greater drug exposure and fewer adverse events typically associated with PDE4 inhibitors –– First-in-human achievement of target exposure with proprietary transdermal patch formulation developed in partnership with MEDRx –– Proof-of-concept study in cognitive impairment associated with schizophrenia (CIAS) to be initiated in the first half of 2024 – LOS ALTOS, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced positive results from its healthy volunteer Phase 1 study of ALTO-101, a novel PDE4 inhibitor in development for cognitive impairment associated with schizophrenia (CIAS). Results from the study demonstrated favorable tolerability and improved pharmacokinetics of ALTO-101 when administered via a transdermal delivery system (TDS) compared to oral administration. The TDS formulation is being developed in partners
Show less
Read more
Impact Snapshot
Event Time:
ANRO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ANRO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ANRO alerts
High impacting Alto Neuroscience, Inc. news events
Weekly update
A roundup of the hottest topics
ANRO
News
- Alto Neuroscience (ANRO): Strong Industry, Solid Earnings Estimate Revisions [Yahoo! Finance]Yahoo! Finance
- Alto Neuroscience Announces Initiation of Phase 2 Study of ALTO-203 in Patients with Major Depressive DisorderBusiness Wire
- Alto Neuroscience, Inc. (NYSE: ANRO) had its "buy" rating re-affirmed by analysts at Stifel Nicolaus. They now have a $32.00 price target on the stock.MarketBeat
- Alto Neuroscience Reports Full Year 2023 Financial Results and Recent Business HighlightsBusiness Wire
- Alto Neuroscience Appoints Maha Radhakrishnan, M.D., to Board of DirectorsBusiness Wire
ANRO
Sec Filings
- 4/1/24 - Form 4
- 3/29/24 - Form SC
- 3/21/24 - Form 10-K
- ANRO's page on the SEC website